ProShare Advisors’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

ProShare Advisors’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,275	Closed	-$105K	–	2251
2022 Q1	$105K	Sell	11,275 -2,823	-20%	-$30K	﹤0.01%	2022
2021 Q4	$200K	Sell	14,098 -378	-3%	-$6.54K	﹤0.01%	2033
2021 Q3	$336K	Sell	14,476 -2,379	-14%	-$56.2K	﹤0.01%	1467
2021 Q2	$420K	Buy	16,855 +2,574	+18%	+$69.2K	﹤0.01%	1664
2021 Q1	$400K	Buy	14,281 +4,120	+41%	+$149K	﹤0.01%	1603
2020 Q4	$355K	Buy	+10,161	New	+$442K	﹤0.01%	1503

Other funds holding FMTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

EPL

EDBI Pte Ltd Singapore $94.4M AUM 32.71% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ProShare Advisors's FMTX Position: Q2 2022 in Review

ProShare Advisors sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q2 2022, closing a stake of 11,275 shares — an estimated $105K sold.

ProShare Advisors first reported a position in FMTX in Q4 2020 and held it in 6 quarters. The position peaked at $420K in Q2 2021. 105 funds tracked by Wall St. Rank hold FMTX as of Q2 2022.

ProShare Advisors reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 11,275 Forma Therapeutics Holdings, Inc. Common Stock shares in Q2 2022, an estimated $105K.
ProShare Advisors first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
ProShare Advisors's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $420K in Q2 2021.
105 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.